When asked about the company’s financials, Sapirstein said:
Balance sheet is “pretty strong.” ContraVir is not looking to raise money right now. Maybe next year, an opportunity to raise cash arises, given the right conditions. Partners might be another way to go – and there are “several potential partners” the company is talking to. They will probably need money by the end of next year, as they will have three drugs in the clinic.
News 
Market Data 
Discover 
